WallStSmart

Precision BioSciences Inc (DTIL)vsRegeneron Pharmaceuticals Inc (REGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Regeneron Pharmaceuticals Inc generates 37412% more annual revenue ($16.90B vs $45.04M). REGN leads profitability with a 28.5% profit margin vs -85.6%. REGN trades at a lower P/E of 21.0x. REGN earns a higher WallStSmart Score of 80/100 (B+).

DTIL

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.5
Piotroski: 2/9Altman Z: -3.79

REGN

Strong Buy

80

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DTILUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$9.38

Current Price

$7.28

$2.10 discount

UndervaluedFair: $9.38Overvalued
REGNUndervalued (+36.3%)

Margin of Safety

+36.3%

Fair Value

$1500.88

Current Price

$952.40

$548.48 discount

UndervaluedFair: $1500.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DTIL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37272.0%10/10

Revenue surging 37272.0% year-over-year

REGN6 strengths · Avg: 9.7/10
Operating MarginProfitability
30.4%10/10

Strong operational efficiency at 30.4%

Revenue GrowthGrowth
36.3%10/10

Revenue surging 36.3% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$98.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.5%9/10

Keeps 29 of every $100 in revenue as profit

Areas to Watch

DTIL4 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

REGN1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DTIL

The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.

Bear Case : DTIL

The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score.

Key Dynamics to Monitor

DTIL profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.35 — expect wider price swings.

DTIL is growing revenue faster at 37272.0% — sustainability is the question.

REGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

REGN scores higher overall (80/100 vs 26/100), backed by strong 28.5% margins and 36.3% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?